

# **Nitric Oxide**

## **Therapeutics, Markets and Companies**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**December 2017**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech.

Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons. Updated material from both these books have been included in 2017 edition of a special report on Gene Therapy published by Jain PharmaBiotech Publications. Prof. Jain has edited "Drug Delivery Systems" (Humana/Springer 2008; 2<sup>nd</sup> ed 2014) and "Drug Delivery to the Central Nervous System" (Humana/Springer 2010). His other recent books include "Handbook of Nanomedicine" (Springer 2008; Chinese edition, Peking University Press 2011, 2<sup>nd</sup> ed Springer 2012, 3<sup>rd</sup> ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2<sup>nd</sup> ed Springer 2018, in press), "Handbook of Neuroprotection" (Springer 2011), "Application of Biotechnology in Cardiovascular Disorders" (Springer 2011), "Application of Biotechnology in Neurology" (Springer 2013), and "Application of Biotechnology in Oncology" (Springer 2014). Some of these books contain chapters on nitric oxide. He has edited "Applied Neurogenomics" (Springer 2015).

**December 2017 (first edition published in 2002)  
Copyright © 2017 by**

**Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland**

**Tel & Fax:      +4161-6924461  
Email:            info@pharmabiotech.ch  
Web site:        http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>13</b>
<b>1. Introduction .....</b>	<b>15</b>
<b>Nitric oxide .....</b>	<b>15</b>
Historical aspects.....	15
<b>Free radicals .....</b>	<b>16</b>
Nitrogen cycle and NO.....	16
Role of NO in biology and medicine .....	17
<b>Nitric oxide synthase .....</b>	<b>18</b>
Structure and function NOS.....	18
Inducible nitric oxide synthase.....	20
<i>iNOS gene</i> .....	20
<i>Regulation of iNOS</i> .....	20
Regulation of endothelial nitric oxide synthase.....	20
<i>Interaction between eNOS and other proteins</i> .....	21
<i>Tetrahydrobiopterin</i> .....	21
<i>eNOS gene</i> .....	22
<b>NOS-independent NO generation and circulation .....</b>	<b>22</b>
Entero-salivary circulation of nitrate.....	22
<b>Methods of study of NO and NOS .....</b>	<b>23</b>
Colorimetric determination of NO <sub>2</sub> <sup>-</sup> using the Greiss reagent.....	23
Chemiluminescence.....	24
High performance liquid chromatography .....	24
Bioimaging of NO .....	24
Electrochemical methods using amperometry .....	25
Method using micro ion electrodes .....	25
Metabolomics approach to study of NO metabolism .....	25
<b>2. Nitric Oxide Pathways .....</b>	<b>27</b>
<b>Introduction .....</b>	<b>27</b>
<b>Mechanisms action of NO .....</b>	<b>28</b>
NO-cGMP pathway .....	28
Nitrate-nitrite-NO pathway.....	29
Soluble guanylyl cyclase as the NO receptor .....	29
<b>Oxidative stress pathways .....</b>	<b>29</b>
NO and oxidative stress.....	30
Oxidative stress and the NO-cyclic GMP signal transduction pathway .....	30
NO and platelets.....	32
Mitochondrial NO-cytochrome c oxidase signaling pathway.....	32
Nitric oxide and cytochrome c oxidase .....	33
Dual role of NO as a free radical and a scavenger .....	34
<b>NO and carbon monoxide.....</b>	<b>34</b>
<b>NO signaling and apoptosis.....</b>	<b>35</b>
<b>3. Role of NO in Physiology.....</b>	<b>37</b>
<b>Homeostasis of NO .....</b>	<b>37</b>
<b>Role of NO in adaptation to high altitude .....</b>	<b>37</b>
<b>NO as a biomarker .....</b>	<b>38</b>
<b>Functions of NO in various systems of the body.....</b>	<b>38</b>
NO and proteins.....	39
<i>A proteomic method for identification of cysteine S-nitrosylation sites</i> .....	39
<i>Protein S-nitrosylation and intracellular transport processes</i> .....	39
<i>Cellular inactivation NO by iNOS aggresome formation</i> .....	39
NO and mitochondria.....	40
<i>Mitochondrial permeability and reperfusion injury</i> .....	41
Endocrine role of NO .....	41
Role of NO in the cardiovascular system .....	41
<i>NO and atrial natriuretic peptide</i> .....	42
<i>NOS in the cardiac myocyte</i> .....	42
<i>NO and the autonomic control of the heart rate</i> .....	43
<i>NO and vascular system</i> .....	44
<i>NO and vasodilatation</i> .....	45
<i>NO and blood pressure</i> .....	46
<i>Role of NO in the plasma compartment</i> .....	46
<i>Measurement of NO as a biomarker of cardiovascular function</i> .....	47
Hemoglobin, oxygen and nitric oxide.....	47
<i>Myoglobin and NO</i> .....	48
NO and pulmonary circulation.....	49

<i>Role of NO in the regulation of hypoxic pulmonary vasoconstriction</i> .....	49
Role of NO in the lymphatic system .....	49
Role of NO in the nervous system .....	50
<i>Neurovascular coupling of COX-2 and nNOS</i> .....	51
<i>Neuroglobin</i> .....	51
<i>NO and blood-brain barrier</i> .....	52
<i>NO as a neurotransmitter</i> .....	52
<i>Role of NO in memory and learning</i> .....	52
<i>Role of NO in synaptic plasticity</i> .....	53
<i>Role of NO in the peripheral nervous system</i> .....	53
Role of NO in the cochlea.....	53
NO and neuroendocrine function .....	53
NO and pregnancy .....	54
Role of NO in penile erection .....	54
Role of NO in immune regulation .....	55
Role of NO in temperature regulation .....	55
Role of NO in gastrointestinal system .....	56
Role of NO in kidney function .....	56
Role of NO in liver.....	57
Role of NO in the skin.....	57
<b>4. Role of NO in Diseases.....</b>	<b>59</b>
<b>Introduction .....</b>	<b>59</b>
Cytotoxicity of reactive nitrogen species .....	59
Peroxynitrite, mitochondria and cell death.....	59
<b>Diseases involving oxidative stress and nitric oxide .....</b>	<b>61</b>
<b>Stress-related disorders .....</b>	<b>62</b>
<b>Role of NO in allergic disorders.....</b>	<b>62</b>
<b>Inflammatory diseases .....</b>	<b>63</b>
<b>Autoimmune disorders.....</b>	<b>63</b>
Role of NO in rheumatoid arthritis.....	64
<b>Role of NO in infections .....</b>	<b>65</b>
NO-mediated cytoprotection in bacteria .....	65
Nanoscale nanoparticle delivery for cutaneous infection .....	66
Leishmaniasis.....	66
Malaria and iNOS polymorphism .....	66
Susceptibility of <i>Mycobacterium leprae</i> to NO .....	67
Role of NO in the treatment of tuberculosis .....	67
Septic shock.....	67
Trypanosomiasis.....	68
Viral infections.....	68
<b>Role of NO in anaphylactic shock .....</b>	<b>69</b>
<b>Role of NO in anemia and hypoxia .....</b>	<b>70</b>
<b>Role of NO in neurological disorders.....</b>	<b>70</b>
Neurodegenerative diseases.....	70
<i>NO-induced mitochondrial dysfunction in neurodegeneration</i> .....	71
<i>White matter disorders</i> .....	71
<i>Amyotrophic lateral sclerosis</i> .....	71
<i>Alzheimer's disease</i> .....	72
<i>Role of NO in pathophysiology of Alzheimer's disease</i> .....	72
<i>Role of ApoE genotype</i> .....	75
<i>Parkinson's disease</i> .....	75
Traumatic brain injury .....	77
Epilepsy.....	78
Stroke .....	78
<i>Pathophysiology of cerebral ischemia</i> .....	78
<i>Role of NO in cerebral ischemia</i> .....	79
<i>eNOS gene polymorphisms as predictor of cerebral aneurysm rupture</i> .....	81
<i>Role of NO in assessment of cerebral and retinal blood flow</i> .....	81
<i>Role of NO in cerebral vasospasm after subarachnoid hemorrhage</i> .....	81
<i>Role of NO in neuroprotection</i> .....	82
<i>Stroke and heart disease</i> .....	82
Role of NO in peripheral neuropathy .....	83
<i>iNOS induction in experimental allergic neuritis</i> .....	83
<i>Role of NO in sciatica</i> .....	83
Role of NO in the pathogenesis of muscular dystrophy.....	83
Role of NO in neurological decompression sickness.....	84
<b>Role of NO in psychiatric disorders .....</b>	<b>84</b>
NO-dysregulation in schizophrenia .....	84
<b>Role of NO in pathomechanism of cardiovascular disorders.....</b>	<b>85</b>
Oxidative stress as a cause of cardiovascular disease .....	85

Role of NO in pathomechanism of cardiovascular diseases.....	85
<i>Role of iNOS in cardiovascular disease</i> .....	86
<i>Role of eNOS in cardiovascular disease</i> .....	86
<i>Role of nNOS in cardiac arrhythmia and sudden death</i> .....	87
NO and atherosclerosis.....	87
Role of NO in cardiopulmonary disorders.....	89
Role of NO in disturbances of vasodilation.....	89
<i>Caveolin-1 deficiency impairs NO synthesis and vasodilation</i> .....	89
Role of NO in hypercholesterolemia.....	90
NO and systemic hypertension.....	90
Coronary artery disease.....	92
Role of NO in the pathophysiology of angina pectoris.....	92
Congestive heart failure.....	92
<i>Calcium overload as a cause of heart failure</i> .....	93
<i>NO/redox disequilibrium in the failing heart</i> .....	93
Myocardial ischemia/reperfusion injury.....	93
NO pathway in cardiac hypertrophy.....	95
<b>Role of NO in sickle cell disease.....</b>	<b>95</b>
<b>Role of NO in pulmonary disorders.....</b>	<b>95</b>
Role of NO in the pathophysiology of asthma.....	95
<i>iNOS gene polymorphisms in asthma</i> .....	97
<i>Role of S-nitrosoglutathione in bronchodilation in asthma</i> .....	97
Monitoring of exhaled NO.....	98
Nasal NO as a biomarker of response to rhinosinusitis therapy.....	99
Elevated urinary NO as a biomarker of improved survival in ARDS.....	99
Pulmonary hypertension.....	99
<b>Role of NO in renal disorders.....</b>	<b>100</b>
Role of NOS in diabetic nephropathy.....	100
<b>Role of NO in cancer.....</b>	<b>101</b>
Inflammation, NO and colon cancer.....	102
Tumor hypoxia and NO.....	102
NO and p53 mutations.....	103
NO and matrix metalloproteinase.....	103
Role of NO in angiogenesis in cancer.....	103
<b>Role of NO in diseases of the eye.....</b>	<b>104</b>
Glaucoma.....	105
<b>Role of NO in metabolic disorders.....</b>	<b>105</b>
Metabolic syndrome.....	105
Obesity.....	105
Diabetes mellitus.....	105
<b>Role of NO in gastrointestinal disorders.....</b>	<b>106</b>
Role of L-arginine in intestinal adaptation.....	106
Role of NO in irritable bowel syndrome.....	106
Role of NO in inflammatory bowel diseases.....	107
Role of NO in celiac disease.....	107
Role of NO in diabetic gastroparesis.....	107
<b>NO and diseases of the liver.....</b>	<b>108</b>
Cirrhosis of liver.....	108
Hepatic encephalopathy.....	108
<b>Role of NO in skin disorders.....</b>	<b>108</b>
Role of NO and oxidative stress in the aging skin.....	108
Role of NO in wound healing.....	109
<b>Role of NO in erectile dysfunction.....</b>	<b>110</b>
<b>Role of NO in pain.....</b>	<b>110</b>
NO and pain of spinal cord origin.....	110
NO interaction with other receptors in pain.....	111
nNOS and pain.....	111
Role of NO in various types of pain.....	111
<i>Neuropathic pain</i> .....	111
<i>Role of NO in diabetic neuropathy</i> .....	111
<i>NO in oral and facial pain</i> .....	112
<i>Role of NO in migraine</i> .....	112
<i>Role of NO in osteoarthritis</i> .....	113
<i>NO and Fibromyalgia syndrome</i> .....	113
<i>Role of spinal NO in analgesic action</i> .....	114
<b>Role of NO in nicotine addiction.....</b>	<b>114</b>
<b>Role of NO in carbon monoxide poisoning.....</b>	<b>115</b>
<b>Role of NO in chemically-induced toxicity.....</b>	<b>115</b>
Peroxynitrite and drug-dependent toxicity.....	115
Paraquat neurotoxicity.....	115
<b>Role of NO in radiation damage.....</b>	<b>116</b>

<b>5. Pharmacology of Nitric Oxide .....</b>	<b>117</b>
<b>Introduction Source: Fosen and Thom 2014 .....</b>	<b>117</b>
<b>Cytotoxic vs cytoprotective role of NO .....</b>	<b>117</b>
<b>Antioxidants .....</b>	<b>117</b>
<i>Ebselen</i> .....	118
<i>Nicaraven</i> .....	118
<i>Nitroxides</i> .....	119
Antioxidants in relation to NO .....	119
Nitric oxide as an antioxidant .....	119
<b>NO-related drugs .....</b>	<b>120</b>
Drugs that activate eNOS production.....	122
<i>Aspirin</i> .....	122
<i>Dehydroepiandrosterone</i> .....	122
Drugs that scavenge free radicals/NO.....	122
<i>Peroxynitrite scavengers</i> .....	122
<i>Ruthenium (III) polyaminocarboxylates</i> .....	123
<i>Nitrones</i> .....	123
Drugs that inhibit NO.....	123
<i>Ginko biloba</i> .....	123
<i>Epigallocatechin</i> .....	124
<b>Delivery of nitric oxide.....</b>	<b>124</b>
Targeted delivery of NO donors .....	125
Nitric oxide delivery by encapsulated cells.....	125
NO-lipid combination .....	125
NO-releasing coating to prevent infection of implanted devices.....	126
Nanoparticles for controlled/sustained release of NO .....	126
<i>Hydrogel/glass nanoparticles</i> .....	126
<i>Delivery of nanoparticles to vascular endothelium for release of NO</i> .....	126
Release of NO in tissues by extracorporeal shock wave application.....	126
<b>Nitric oxide donors .....</b>	<b>127</b>
Nitroglycerine/glycerine trinitrate.....	127
Isosorbide dinitrate .....	128
Sodium nitrite .....	128
Organic nitrites.....	128
NO-releasing NSAIDs .....	129
COX-inhibiting NO-donors .....	130
Grafting of NO-releasing structures on to existing drugs .....	131
Mesoionic Oxatriazoles .....	133
Cysteine-containing NO donors.....	133
Sodium nitroprusside.....	133
Syndnonimines .....	134
S-Nitrosothiols.....	134
Diazeniumdiolates.....	135
COX-2 inhibitors .....	135
NO hydrogels .....	136
Novel NO donors.....	136
NO mimetics .....	136
Comparison of classical nitrates, grafted NO donors, and NO mimetics .....	137
NO donors and soluble guanylate cyclase activation .....	137
NO donors for increasing the efficacy of chemotherapy .....	138
<b>Factors that enhance availability of NO .....</b>	<b>138</b>
Modulators of cyclic guanosine-3',5'-monophosphate-dependent protein kinases.....	139
<b>NOS-modulating drugs.....</b>	<b>140</b>
Drugs that activate eNOS.....	140
<i>Statins</i> .....	140
<i>Angiotensin converting enzyme inhibitors</i> .....	141
<i>17 Beta-estradiol</i> .....	141
<i>C-2431</i> .....	141
NOS inhibitors .....	141
<i>Rationale of NOS inhibitors</i> .....	141
<i>L-Arginine</i> .....	143
<i>Design of NOS inhibitors</i> .....	143
<i>Selective iNOS inhibitors</i> .....	144
<i>Non-amino acid-based inhibitors</i> .....	145
<i>Aminoguanidine</i> .....	145
<i>Heme ligands</i> .....	146
<i>Pterin antagonists</i> .....	146
<i>Fused-ring bio-isoteric models of arginine as NOS inhibitors</i> .....	146
<i>nNOS inhibitors</i> .....	146
<i>Lubeluzole</i> .....	148
<i>Neurotrophic factors</i> .....	148

<i>Therapies based on action of NOS as a paraquat diaphorase</i> .....	148
<i>Concluding remarks about NOS inhibiting drugs</i> .....	149
<b>NO and stem cell-based therapy</b> .....	<b>149</b>
<b>Nitric oxide and gene therapy</b> .....	<b>150</b>
NOS gene transfer .....	150
Inhibition of NOS by antisense technology .....	151
<b>Drugs that modulate NO action on platelets</b> .....	<b>151</b>
Action of NO and NO donors on platelets .....	152
NOS inhibitors and NO scavengers .....	152
<b>Phosphodiesterase inhibitors</b> .....	<b>152</b>
<b>Activators of soluble guanylate cyclase</b> .....	<b>152</b>
YC-1 .....	152
A-350619 .....	153
Cinaciguat .....	153
<b>Secondary role of NO in the action of drugs</b> .....	<b>153</b>
Selective serotonin reuptake inhibitors .....	153
P2Y receptors and NO .....	154
Calcium channel blockers and NO .....	154
Nitric oxide-based transdermal drug delivery .....	154
Mechanism of resistance of NO-based drugs .....	154
<b>NO and nutraceuticals</b> .....	<b>155</b>
L-arginine as a nutraceutical .....	155
Nitrate and nitrite .....	156
Oleuropein .....	156
Role of NO in beneficial effects of chocolate .....	156

<b>6. Therapeutic Applications</b> .....	<b>157</b>
<b>Introduction</b> .....	<b>157</b>
<b>Role of NO in the management of pulmonary disorders</b> .....	<b>157</b>
Manufacture of NO gas for inhalation .....	157
NO inhalation for acute respiratory distress syndrome .....	157
<i>NO inhalation for premature children with pulmonary dysplasia</i> .....	158
<i>NO inhalation for premature children with respiratory failure</i> .....	158
Pulmonary hypertension .....	159
<i>NO-based treatment of pulmonary hypertension</i> .....	159
<i>Pediatric pulmonary hypertension</i> .....	159
<i>Gene therapy for pulmonary hypertension</i> .....	160
<i>Clinical trials of NO therapies for pulmonary arterial hypertension</i> .....	161
Asthma .....	162
<i>iNOS inhibitors for asthma</i> .....	162
<i>NO for bronchodilation in asthma</i> .....	162
Role of NO in acute lung injury after smoke inhalation .....	162
<b>Cardiovascular disorders</b> .....	<b>163</b>
Role of NO in cardioprotection .....	163
Role of NO in the management of myocardial infarction .....	164
Role of NO in the management of hypertension .....	165
Role of NO in the management of angina pectoris .....	166
Role of NO in therapy of coronary heart disease .....	166
NO-releasing aspirin in patients undergoing CABG .....	167
Management of coronary restenosis .....	167
<i>Modified NO donors</i> .....	167
<i>NO-generating stent for coronary restenosis</i> .....	168
<i>eNOS gene therapy for restenosis</i> .....	169
NO-based management of cardiac hypertrophy .....	169
Congestive heart failure .....	170
<i>Limitation of antioxidant therapy in congestive heart failure</i> .....	170
<i>NO-based therapies for congestive heart failure</i> .....	170
<i>eNOS gene therapy for congestive heart failure</i> .....	170
<i>Gene transfer of nNOS in congestive heart failure</i> .....	170
NO-based therapy for management of cardiogenic shock .....	171
NO-based therapy for cardiac arrhythmias .....	171
Prophylaxis of cardiovascular disorders .....	171
<i>Prevention of atherosclerosis with aging</i> .....	172
Role of iNO in cardiac surgery .....	172
Strategies for increasing NO signaling in cardiovascular disorders .....	172
Peripheral vascular disorders .....	173
<i>Peripheral atherosclerotic arterial disease</i> .....	173
<i>Peripheral ischemic disease</i> .....	173
<i>An eNOS mutant as therapeutic for peripheral vascular ischemia</i> .....	174
<i>Sodium nitrite therapy for peripheral vascular ischemia</i> .....	174
<i>Raynaud's phenomenon</i> .....	174

<b>Neurological disorders</b> .....	<b>175</b>
Cerebrovascular ischemic disorders.....	175
<i>Attenuation of NO for neuroprotection in cerebral ischemia</i> .....	175
<i>Use of NO donors in cerebral ischemia</i> .....	176
<i>Use of NO donors in cerebral reperfusion injury</i> .....	176
<i>NO-based treatments for cerebral vasospasm due to SAH</i> .....	177
<i>NOS gene therapy for cerebral vasospasm</i> .....	177
Degenerative CNS disorders.....	178
<i>Statins for Alzheimer's disease</i> .....	178
<i>NO mimetics for Alzheimer's disease</i> .....	178
<i>iNOS inhibitors for treatment of Alzheimer's disease</i> .....	179
<i>NO-NSAIDs for Alzheimer's disease</i> .....	179
<i>Ginko biloba for Alzheimer's disease</i> .....	179
<i>Personalization of NO-based therapy for Alzheimer's disease</i> .....	180
Role of NO in the treatment of traumatic brain injury.....	180
Neuroinflammatory disorders.....	180
Role of NO-releasing sodium nitroprusside in the treatment of schizophrenia.....	181
Antidepressant effect of NOS inhibitors.....	181
Muscular dystrophy.....	181
Vestibulotoxicity.....	182
NO for opening the blood-brain barrier.....	182
<b>Cochlear disorders</b> .....	<b>183</b>
Cochlear ischemia.....	183
Role of NO in sensoryneural hearing loss.....	183
Ophthalmic disorders.....	183
<i>Glaucoma</i> .....	183
<b>Pain</b> .....	<b>184</b>
NO-based therapies for pain.....	184
Treatment of diabetic neuropathy with isosorbide dinitrate spray.....	184
NO-based therapies for migraine.....	185
NO-based therapy for fibromyalgia syndrome.....	185
<b>NO-based therapies for inflammatory disorders</b> .....	<b>185</b>
<b>NO-based therapies for gastrointestinal disorders</b> .....	<b>185</b>
Protection of gastrointestinal injury from NSAIDs.....	185
Role of NO in the treatment of inflammatory bowel disease.....	186
Topical nitroglycerin for chronic anal fissure.....	186
<b>Cancer</b> .....	<b>187</b>
Mechanism of action of NO in cancer.....	187
Antineoplastic effect of iNOS-expressing cells.....	187
Role of NO in drug resistance of cancer.....	187
Role of NO in treatment of brain tumors.....	188
NO-induced apoptosis.....	188
Role of NO in antiangiogenesis therapies in cancer.....	189
NO donors for the treatment of cancer.....	189
NO-releasing NSAIDs and colon cancer chemoprevention.....	189
Rationale of combining NO aspirin with cancer vaccines.....	190
NO-based cancer gene therapy.....	190
Transdermal nitroglycerine for prostate cancer.....	191
<b>NO-based therapies for skin disorders</b> .....	<b>191</b>
NO-based therapies for skin infections.....	191
Role of NO in the treatment of psoriasis.....	192
<b>NO-based therapy for sickle cell anemia</b> .....	<b>192</b>
Inhaled NO for acute respiratory distress syndrome in sickle cell disease.....	192
NO inhalation for pulmonary hypertension in sickle cell anemia.....	193
<b>Role of NO in disorders associated with pregnancy</b> .....	<b>193</b>
Pre-eclampsia and intra-uterine growth restriction.....	193
Use of NO donors in management of labor.....	194
<b>Erectile dysfunction</b> .....	<b>194</b>
Selective inhibitors of phosphodiesterase 5.....	194
Erectile dysfunction in diabetes.....	195
NO-donating substances for treatment of ED.....	195
NOS gene transfer for ED.....	196
<b>Organ transplant rejection</b> .....	<b>196</b>
<b>Role of NO in the treatment of renal disorders</b> .....	<b>197</b>
<b>Role of NO in the treatment of hepatic disorders</b> .....	<b>198</b>
Portal hypertension.....	198
NO inhalation for restoration of liver function following transplantation.....	198
<b>Role of NO in blood transfusion</b> .....	<b>198</b>
<b>Role of NO in the treatment of osteoporosis</b> .....	<b>199</b>
<b>NO-based wound healing</b> .....	<b>199</b>

<b>7. Evaluation of NO-Based Drugs .....</b>	<b>201</b>
<b>Current status.....</b>	<b>201</b>
<b>Antioxidant vs. NO-based approaches .....</b>	<b>201</b>
<b>SWOT analysis of selected approaches for NO modulation.....</b>	<b>201</b>
NO donors by grafting of NO-releasing structures .....	201
NOS modulation .....	202
<b>Challenges of developing NO-based therapies .....</b>	<b>203</b>
<b>Concluding remarks and future prospects.....</b>	<b>203</b>
<b>8. Markets for NO-based Therapies.....</b>	<b>205</b>
<b>Introduction .....</b>	<b>205</b>
<b>Impact of NO-based therapies on international markets .....</b>	<b>205</b>
<b>Share of NO-based therapies in major therapeutic areas.....</b>	<b>205</b>
<b>Share of NO-based therapies in cardiovascular disorders .....</b>	<b>206</b>
Hypercholesterolemia .....	206
Myocardial infarction .....	207
Angina pectoris/coronary artery disease .....	207
Heart failure.....	207
Coronary restenosis and stenting .....	207
<b>Strategies for developing NO-based therapy markets.....</b>	<b>207</b>
Addressing the unfulfilled needs.....	208
Multidisciplinary approaches.....	208
Collaboration between the academia and the industry .....	209
Education of the public .....	209
<b>9. Companies .....</b>	<b>211</b>
<b>Introduction .....</b>	<b>211</b>
<b>Profiles of companies with focus on NO .....</b>	<b>213</b>
<b>Major pharmaceutical companies with involvement in NO .....</b>	<b>224</b>
<b>Smaller biotech and pharmaceutical companies involved in NO.....</b>	<b>228</b>
<b>Biopharmaceutical companies involved in antioxidant research .....</b>	<b>238</b>
<b>Companies supplying NO equipment for healthcare.....</b>	<b>242</b>
<b>Academic institutes with commercial collaboration in NO research .....</b>	<b>246</b>
<b>Companies supplying NO products for research.....</b>	<b>247</b>
<b>Collaborations.....</b>	<b>251</b>
<b>10. References.....</b>	<b>253</b>

## Tables

Table 1-1: Historical landmarks in the discovery and applications of nitric oxide .....	15
Table 3-1: Important functions of NO in the human body.....	38
Table 4-1: Diseases involving nitric oxide .....	61
Table 4-2: Role of nitric oxide in pathogenesis of autoimmune disorders.....	64
Table 4-3: Role of nitric oxide in infections.....	65
Table 5-1: Neuroprotective antioxidants .....	117
Table 5-2: NO-related drugs .....	120
Table 5-3: Methods of delivery of nitric oxide .....	124
Table 5-4: Comparison of classical nitrates, grafted NO donors, and NO mimetics.....	137
Table 5-5: Classification of NOS inhibitors.....	142
Table 5-6: Potential clinical applications of gene transfer for NOS overexpression .....	150
Table 6-1: Clinical trials of NO-based therapies for pulmonary hypertension.....	161
Table 6-2: Cardiovascular disorders for which NO-based therapies are used.....	163
Table 6-3: Selected neurological applications of NO-based therapies .....	175
Table 6-4: NO-related therapies for pain.....	184
Table 7-1: SWOT of technology – NO donors by grafting of NO-releasing structures.....	202
Table 7-2: SWOT of products – NO donors by grafting of NO-releasing structures .....	202
Table 7-3: SWOT of NOS gene manipulation .....	202
Table 7-4: SWOT of analgesic development by NOS isoform targeting .....	203
Table 8-1: Share of NO-based therapies in relevant therapeutic areas 2016-2026 .....	206
Table 8-2: Share of NO-based therapies in cardiovascular diseases 2016-2026 .....	206
Table 9-1: Classification of companies involved in NO and antioxidant therapies.....	212
Table 9-2: NicOx products in development.....	218
Table 9-3: NO-related products of Sigma Aldrich .....	249
Table 9-4: Collaborations of companies relevant to nitric oxide.....	251

## Figures

Figure 1-1: Nitrogen cycle in the human body .....	17
Figure 1-2: Biosynthesis of nitric oxide (NO) .....	18
Figure 1-3: NO synthase pathway .....	19
Figure 2-1: Reactivity of nitric oxide with heme proteins in oxygen or peroxide reaction cycles.....	27
Figure 2-2: NO-cGMP pathway leading to vasorelaxation .....	28
Figure 2-3: The biological pathways toward protein nitration.....	30
Figure 2-4: NF- $\kappa$ B activation and iNOS induction.....	31
Figure 2-5: Overview of mitochondrial NO-cytochrome c oxidase signaling pathway.....	33
Figure 3-1: Role of NO in adaptation to high altitude.....	37
Figure 3-2: NOS in the cardiac myocyte .....	43
Figure 3-3: Pathways for generation and inhibition of NO in the vasculature.....	44
Figure 3-4: Interactions of the Mb compounds with O <sub>2</sub> and NO .....	48
Figure 3-5: Role of NO in dynamics of lymphatic pumping .....	50
Figure 4-1: Molecular mechanisms of peroxynitrite-mediated cell death.....	60
Figure 4-2: NO neurotoxicity and neuroprotection in relation to Alzheimer's disease.....	74
Figure 4-3: Some steps in the ischemic cascade and site of action of neuroprotectives .....	79
Figure 4-4: Dual role of nitric oxide (NO) in cerebral ischemia .....	80
Figure 4-5: Blood cell-endothelial cell interactions induced by hypercholesterolemia.....	90
Figure 4-6: Effects of NO on the pathophysiology of myocardial ischemia-reperfusion .....	94
Figure 4-7: Nitric oxide: tumor enhancement or inhibition .....	101
Figure 4-8: Role of nitric oxide in angiogenesis.....	104
Figure 4-9: Role of NO in HBO-induced wound healing .....	109
Figure 5-1: Nitrogen oxide mimetics – synergy by chemical modification .....	136
Figure 5-2: Factors that enhance availability of NO .....	139
Figure 5-3: Mechanism of resistance to NO-based therapeutics .....	155
Figure 6-1: Mechanism of development of tolerance to glyceryl trinitrate .....	165
Figure 6-2: Vicious circle of vascular occlusion following angioplasty and stenting.....	168
Figure 6-3: PDE5 inhibition and the response to sexual stimulation .....	195
Figure 8-1: Unfulfilled needs in NO therapeutics .....	208